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Abstract 
 
Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalisation in 
young children less than 2 years of age in the UK. Respiratory Syncytial Virus (RSV) is the 
most common virus associated with bronchiolitis and has the highest disease severity, 
mortality and cost.  Bronchiolitis is generally a self-limiting condition, but can have serious 
consequences in infants who are very young, premature, or have underlying co-
morbidities. Management of bronchiolitis in the UK is guided by the National Institute of 
Clinical Excellence (NICE) guidance published in 2015. Currently, the mainstays of 
management are largely supportive, consisting of fluid management and respiratory 
support. Pharmacological interventions including nebulised bronchodilators, steroids and 
antibiotics generally have limited or no evidence of efficacy and are not advised by NICE.  
Anti-viral therapeutics remain in development. 
 
As treatments are limited, there have been extensive efforts to develop vaccines.  As the 
major cause of bronchiolitis, RSV has been the main target for vaccines.  At present, the 
only licensed product is a monoclonal antibody for passive immunisation.  Its cost restricts 
its use to those at highest risk.  Vaccines for active immunisation of pregnant women and 
young infants are also being developed.  
1 
Introduction 
Bronchiolitis, an acute respiratory illness, is the leading cause of hospitalization in children 
less than 2 years of age in developed countries (Hasegawa et al. 2013). In the UK, 2–3% 
of all infants less than 12 months of age will be hospitalised with bronchiolitis (Murray et al. 
2014). Bronchiolitis is caused by respiratory viruses that invade the epithelial cells of the 
small airways leading to excessive mucus production, obstruction of the bronchioles, 
varying degrees of bronchospasm and air trapping.  Respiratory syncytial virus (RSV) is 
the most common virus associated with bronchiolitis, followed by rhinovirus, parainfluenza 
virus, human metapneumovirus, influenza virus, adenovirus, coronavirus and human 
bocavirus. In roughly one third of the cases, more than one virus is detected (Mansbach et 
al. 2012). 
 
Bronchiolitis begins with upper respiratory tract symptoms of rhinorrhoea followed by 
persistent cough, tachypnoea, chest wall recessions and widespread crackles, wheeze or 
both, which peak on days three to five and then gradually resolve in most previously 
healthy infants (Florin et al. 2016). In a systematic review including 590 children with mild 
disease that did not require admission to the hospital, cough resolved in half of the cases 
within 2 weeks and in 90% within 3 weeks (Thompson et al. 2013). However, infants less 
than 3 months of age, or born prematurely (less than 32 weeks of gestation) or with 
underlying cardiopulmonary disease (chronic lung disease, haemodynamically significant 
congenital heart disease), or immunodeficiency, or neuromuscular disorders are at high 
risk of severe disease. Most common complications are dehydration, apnoea and 
secondary bacterial infection. A small proportion of infants with bronchiolitis may develop 
respiratory failure and require mechanical ventilation. In addition, an association between 
hospitalisation with RSV bronchiolitis and asthma later in life is increasingly recognised 
(Régnier and Huels 2013). Likewise, higher use of asthma medication has been observed 
during first year after hospitalization in infants  with rhinovirus-positive bronchiolitis (Bergroth et al. 
2016) 
 
In the UK, hospital admission rates for bronchiolitis rose sevenfold between 1979 and 
2011(Green et al. 2016). In this period intensive care admission rates did not increase, 
suggesting that rising hospital admissions for bronchiolitis are not related to changes in 
disease severity but to clinical practice. Much of this increase relates to how readily 
relative hypoxeamia is identified using pulse oximetry.  The high incidence of disease, the 
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lack of a highly effective treatment or preventive intervention and the need for cost-
effective use of healthcare resources led to a large body of research integrated into 
national guidelines that tried to tackle the inconsistency in clinical practice. Multiple studies 
use a range of differing outcome measures, ranging from changes in physiological 
parameters, the need for escalation of therapy through to length of stay.  For the majority 
of admitted infants who will not need intensive care, it is duration of admission that matters 
most.  This is usually driven by duration of supplementary oxygen.  In most cases, ability 
to tolerate feeds recovers prior to dependency on oxygen.  Overall, proxy outcomes such 
as heart rate, respiratory rate, oxygen saturation or work of breathing are considered less 
important than length of admission. 
In England and Wales, the National Institute for Health and Care Excellence (NICE) 
published a guideline for the hospital management of bronchiolitis in 2015 (Table 1,2) 
(NICE 2015). Prior to this, hospital Trusts in the UK based their local guidelines on the 
Scottish Intercollegiate Guideline Network (SIGN) guideline published in 2006 and 
withdrawn in 2015 (SIGN 2006). In this review, we summarise current recommendations 
by NICE on the management and prevention of bronchiolitis, and bring focus onto some 
important more recent publications. 
 
 
Fluid management 
The combination of increased work of breathing, persistent cough and copious nasal 
secretions can affect oral intake. Oxygen supplementation can improve respiratory distress 
to allow adequate fluid intake. Small and frequent feeds are usually tolerated better. For 
those who cannot maintain hydration orally, orogastric or nasogastric feeding may be 
needed. A randomised trial in Australia and New Zealand including 759 infants less than 1 
year of age admitted to hospital with bronchiolitis showed no benefit of intravenous fluids 
compared to nasogastric tube in length of hospital stay (absolute difference 4.5 h 95% CI -
3·9 to 12·9; P=0.30). Nasogastric insertion was easier than intravenous cannulation (first 
attempt success rate 85% vs 56%; P<0.0001) (Oakley et al. 2013). Intravenous fluids 
should be reserved for infants with impeding respiratory failure unable to tolerate enteral 
feeding. In this case, fluid replacement is better restricted to two thirds of maintenance 
requirement to prevent electrolyte imbalance caused by inappropriate secretion of 
antidiuretic hormone (Hanna et al. 2003). 
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Respiratory support  
Respiratory support is generally provided in a stepwise approach. Most children receive 
nasal suctioning. Supplemental oxygen is administered to those with oxygen saturations 
below 92%. Those with more severe disease often receive a trial of heated humidified 
high-flow nasal cannula (HFNC) therapy and/or continuous positive airway pressure 
(CPAP) before endotracheal intubation, although in the most severe cases intubation 
should not be delayed by a trial of non-invasive ventilation.  
 
Nasal suctioning 
Routine suctioning of the nasopharynx is not supported by the existing evidence 
(Mussman et al. 2013). However, it is recommended by NICE for symptomatic relief of 
nasal congestion in infants with apnoeas, respiratory distress or feeding difficulties. NICE 
recommends suctioning in children with apnoea even in the absence of obvious 
secretions. 
 
Supplemental oxygen 
Oxygen is the mainstay of treatment for respiratory distress, and is usually administered 
via nasal cannula, face mask, head box, or wafted near face to minimise handling. Even 
though pulse oxygen saturation is widely used to guide decisions to initiate oxygen 
administration, there is no agreed definition of hypoxaemia in bronchiolitis. In the UK, 
NICE recommends supplemental oxygen when oxygen saturation readings drop below 
92%, while the American Academy of Pediatrics (AAP) suggests a threshold of 90% 
(Ralston et al. 2014). A double-blind, randomised, equivalence trial of 615 infants admitted 
with bronchiolitis in UK compared pulse oxygen saturation of 94% with a lower threshold of 
90% (Cunningham et al. 2015). No difference was found in duration of cough, need for 
invasive respiratory support or rates of readmission, whereas the length of hospital stay 
was shorter in the 90% threshold arm.  This suggests that stopping supplementary oxygen 
therapy in the recovery phase sooner than recommended in current guidelines is likely to 
be safe. 
 
HFNC therapy  
High-flow nasal cannula oxygen (HFNC) is a non-invasive method of ventilation. Its main 
advantage is that allows high flow oxygen to be safely delivered without causing damage 
to the respiratory mucosa because the air is heated and humidified. Its beneficial effect is 
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exerted by reducing the respiratory resistance of the nasal passages and delivering low 
levels of positive airway pressure. In recent years HFNC has been increasingly used for 
the management of bronchiolitis. Despite this, its use is not recommended in the current 
NICE guidelines. A Cochrane review in 2014 concluded that evidence was insufficient to 
determine the effectiveness of HFNC therapy (Mayfield et al. 2014). However, two recent 
randomised trials have shown benefit in preventing PICU admissions and escalation of 
care.  In a randomized controlled trial in a non-ICU setting of 202 children less than 2 
years of age fewer children experienced treatment failure on HFNC at 1 L/kg per minute 
compared with standard therapy (14% versus 33%, risk difference, -19%; 95% CI, -30% to 
-8%; p=0.0016) (Kepreotes et al. 2017). 60% of those who failed on standard treatment 
were subsequently rescued by HFNC and avoided intensive care. Following ‘rescue’, 
intensive care unit admission rates were similar for both groups, implying that HFNC will 
not prevent mechanical ventilation in the most severe cases. In an unmasked randomised 
controlled trial on 17 emergency departments and general paediatric wards in Australia 
and New Zealand that included 1472 infants less than 12 months of age, the use of HFNC 
at 2 L/kg per minute decreased the rate of escalation in care due to treatment failure by 
11% compared to standard oxygen therapy (12% versus 23%, risk difference, -11%; 95% 
CI, -15% to -7%; p<0.001) (Franklin et al. 2018). Interestingly, there was no difference between 
groups in length of hospital stay (approximately 3 days), duration of oxygen therapy (approximately 
2 days), and rate of adverse events (<1%). Further trials are needed to determine the optimal 
flow rate and weaning schedules. 
 
CPAP 
CPAP is widely used in infants with severe bronchiolitis to avoid intubation and PICU 
admission. Its role in improving ventilation and oxygenation has been suggested by 
several observational and randomized studies. A Cochrane review of two randomised 
controlled trials with a total of 50 infants under 12 months of age that compared CPAP with 
standard oxygen therapy showed a reduction on the need for mechanical ventilation, but 
there was a considerable imprecision on estimated effect because of the small size of the 
cohorts (risk ratio (RR) 0.19, 95% CI 0.01 to 3.63; p=0.27) (Jat and Mathew 2015). A 
second systematic review of six observational and two randomized studies also concluded 
that the evidence to support the use of CPAP is inconclusive because of poor 
methodological quality (Donlan et al. 2011). NICE’s recommendation is to consider CPAP 
in children with bronchiolitis who have impending respiratory failure (Table 3).  
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Endotracheal intubation  
Infants with worsening severe distress who fail to improve to standard treatment may 
require endotracheal intubation and mechanical ventilation. Recognition of impending 
respiratory failure is essential to trigger an escalation of care response. 
 
Chest physiotherapy  
Routine chest physiotherapy is not supported by the existing evidence. NICE identified 
seven randomised controlled trials of chest physiotherapy in bronchiolitis. They reported 
no difference in time to recover or need for ventilation between the intervention and the 
control groups. The quality of the evidence available ranged from moderate to very low. 
However, chest physiotherapy may be beneficial in infants with neuromuscular disorders 
or severe tracheomalacia that face additional difficulties to clear secretions or those 
admitted in PICU. 
 
Pharmacological interventions  
 
Bronchodilators (salbutamol, ipratropium, adrenaline) 
Bronchodilators are a well-established treatment for asthma and viral induced wheeze. 
They reverse bronchoconstriction by causing relaxation of the airway smooth muscle. 
Even though the pathogenesis of bronchiolitis is somewhat different from asthma, it is 
proposed that bronchodilators might relieve respiratory distress in patients with 
bronchiolitis. On the other hand, bronchodilators may cause adverse effects (tachycardia 
and tremor) and increase the cost of care. A range of nebulised or inhaled bronchodilators 
including β2 agonists, anticholinergic agents and adrenaline have been trialled. A 
Cochrane Review identified 30 trials involving 1992 infants that compared bronchodilators 
(other than adrenaline) with placebo (Gadomski and Scribani 2014). There was no 
difference in the need for hospitalization (11.9% in bronchodilator group versus 15.9% in 
placebo group, odds ratio (OR) 0.75, 95% CI 0.46 to 1.21), or length of stay (mean 
difference (MD) 0.06, 95% CI -0.27 to 0.39). Because of variable study designs, small 
sample sizes and the lack of standardized validated outcomes, there was considerable 
heterogeneity in the studies included in the meta-analysis. Although routine administration 
of inhaled bronchodilators is not recommended, a small group of children with bronchiolitis 
especially those with wheeze without crackles and/or a personal or family history of atopy 
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may have bronchodilator responsive airway obstruction. The pragmatic approach of a one-
time trial of inhaled salbutamol to distinguish non-responders from responders is often 
hampered by baseline variability in observations within an individual. Apparent 
improvement may often be transient.  
 
Nebulized adrenaline targets both β and α receptors, therefore has bronchodilator effects 
and reduces mucosal oedema. The Canadian Bronchiolitis Epinephrine Steroid Trial, a 
double-blind, placebo-controlled trial involving 800 infants under one year of age showed a 
decrease in hospitalizations 7 days after treatment with combined adrenaline and oral 
dexamethasone compared to placebo (RR 0.65; 95% CL 0.45 to 0.95, P=0.02) (Plint et al. 
2009). However, the result was insignificant after adjusting for multiple comparisons (P = 
.07). A Cochrane Review that included 19 studies with a total of 2256 participants 
concluded that adrenaline reduced rates of admission compared with placebo on the day 
of the ED visit (RR 0.67; 95% CI 0.50 to 0.89) but found no difference at one week 
(Hartling et al. 2011). Taking into consideration the short-term effect of nebulised 
adrenaline and its limited use outside hospital setting, discharging an infant home from the 
ED after nebulised adrenaline administration raises safety concerns. Adrenaline is not 
recommended in children with bronchiolitis except as a rescue agent in hospital.  
 
 
Hypertonic saline (HS) 
The use of hypertonic saline in management of bronchiolitis has been extensively trialled.  
It is believed to improve airway obstruction by increasing mucociliary clearance. A 
Cochrane review from 2013 analysed 11 randomised controlled studies and concluded 
that it reduced the length of stay among hospitalised infants (Zhang et al. 2013). However, 
further studies in recent years reported no benefit. The UK SABRE study, an open label 
non-blinded trial, that randomised 317 infants to receive HS or no nebulised treatment 
showed no difference in time to discharge (Everard et al. 2014). The most recent 
Cochrane review from 2017 of 17 trials involving 1867 infants found low-quality evidence 
that nebulized hypertonic saline compared to normal saline reduces length of stay by 
approximately half day (MD -0.41 days, 95% CI -0.75 to -0.07; P = 0.02, I²= 79%) (Zhang 
et al. 2017). Another meta-analysis found no difference when the data were reanalyzed to 
control for heterogeneity (Brooks et al. 2016). NICE in its recent recommendation 
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concluded that the use of HS did not reduce the length of hospital stay compared to 
standard treatment and recommended against its use.  
 
Glucocorticoids 
Glucocorticoids are part of the standard treatment of children with asthma largely due to 
their anti-inflammatory effects. Their use in bronchiolitis is not supported by the existing 
evidence. A 2013 Cochrane review of 17 trials involving 2596 children under 2 years of 
age with acute bronchiolitis showed that the use of systemic or inhaled glucocorticoids did 
not improve duration of hospital stay or severity of symptoms (Fernandes et al. 2013).  
 
Heliox 
The use of heliox in not recommended in the NICE guidelines for the treatment of 
bronchiolitis.  A 2015 Cochrane review of seven heterogeneous randomized trials 
concluded that heliox did not reduce the rate of intubation, rate of discharge from the 
emergency department, or the length of treatment for respiratory distress (Liet et al. 2015). 
 
Leukotriene inhibitors 
A 2015 Cochrane review of five randomized trials with a total of 1296 infants less than 24 
months of age hospitalised with bronchiolitis found no effect on duration of hospitalization 
or clinical scores (Liu et al. 2015). 
 
Antibiotics 
Antibiotics are not recommended in the treatment of bronchiolitis.  A 2014 Cochrane 
review of seven randomised controlled trials involving 824 infants under 2 years of age 
concluded that there was no evidence to support the use of antibiotics (amoxicillin, 
ampicillin, clarithromycin, azithromycinin, erythromycin) in bronchiolitis (Farley et al. 2014). 
However, antibiotics should be used in cases of concomitant or secondary pneumonia.  It 
must be remembered that chest radiographs in bronchiolitis may show areas of patchy 
atelectasis attributable to the underlying pathology. These can be misinterepreted to 
indicate bacterial lower respiratory tract infection leading to the unnecesary use of 
antibiotics.  Routine radiographs in bronchiolitis should therefore be avoided. 
 
Ribavirin 
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Antiviral drugs such as ribavirin are not recommended in bronchiolitis. A 2007 Cochrane 
review concluded that trials of ribavirin lack sufficient power to provide reliable estimates of 
the effects (Ventre and Randolph 2007). In addition, ribavirin is associated with possible 
carcinogenicity and teratogenicity and there are concerns regarding occupational exposure 
(Mooney et al. 2014). 
 
Anti-RSV preparations 
Palivizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody did not improve 
duration of hospitalization or severity of illness when used for treatment of RSV 
bronchiolitis (Sáez-Llorens et al. 2004). Similar results reported in a trial of motavizumab 
(Ramilo et al. 2014). A number of molecules are currently in pre-clinical or clinical 
development, the most advanced of which is ALS-8176, a RNA polymerase inhibitor which 
has been found to be efficacious in a proof-of-concept human challenge study 
(DeVincenzo et al. 2015). 
 
Prevention of RSV 
RSV bronchiolitis has been shown to have the highest mortality, morbidity and cost, 
particularly in children younger than 6 months of age (Shi et al. 2017). As a result, 
preventative treatment is mainly focused around RSV. Despite ongoing research efforts 
over the last 50 years, there is no validated vaccine to date, and the only treatment 
licensed for RSV prevention worldwide is Palivizumab. 
 
Palivizumab 
Palivizumab is a humanized monoclonal antibody that provides passive 
immunoprophylaxis against RSV (Wegzyn et al. 2014). It is delivered as a monthly 
intramuscular injection that is administered over the RSV season.  
There is extensive evidence that it reduces hospital admission rates and disease severity 
as well as length of hospital stay in preterm infants (<35 weeks) with and without Chronic 
Lung Disease (The Impact-RSV Study Group 1998), and haemodynamically significant 
congenital heart disease (Li et al. 2016). There is also some evidence for use in Down’s 
Syndrome (Yi et al. 2014), while the evidence is still inconclusive in other conditions such 
as Cystic Fibrosis and Neuromuscular disorders (Simões et al. 2018). It is a generally safe 
medication which has been shown to be well-tolerated (Chen et al. 2015; Simões et al. 
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2018). However, at present guidelines in many countries restrict the use of Palivizumab to 
high-risk children only as a result of cost-benefit considerations (AAP 2014). 
Palivizumab is recommended in the UK for 3 groups (PHE 2015): 
1. Lung Disease 
a. Premature babies requiring oxygen or respiratory support at 36 weeks post-
menstrual age as per Figure 1 (Green and light green boxes) 
b. Infants less than 12 months of age at the start of the RSV season on Long 
Term Ventilation (who have failed to be weaned three months after 
mechanical ventilation began) 
c. Infants less than 24 months of age at the start of the RSV season on Long 
Term Ventilation, and significant co-morbidities (eg. Cardiac/Lung pathology) 
2. Congenital Heart Disease 
a. Premature babies with haemodynamically significant, acyanotic congenital 
heart disease of appropriate chronological age as per Figure 1 (Light green 
boxes only) 
b. Cyanotic/Acyanotic congenital heart disease with significant co-morbidities 
particularly if multiple organ systems are involved 
3. Severe Combined Immunodeficiency (SCID) 
a. Children under 24 months of age with SCID, until immune reconstituted 
 
A maximum of 5 doses one month apart from October to the end of February is advised. 
 
Vaccine Candidates 
Despite the efficacy of Palivizumab, its restriction on cost grounds to specific high-risk 
groups means there is still a significant unmet need for preventative treatment against 
RSV (Jaberolansar et al. 2016; Neuzil 2016), as greater than 70% of hospital admissions 
due to RSV Bronchiolitis are for children with no underlying medical condition (Bont et al. 
2016). Unfortunately, early attempts at an RSV vaccine during the 1960s were 
unsuccessful, with vaccinated children having more severe disease (Simões et al. 2018). 
There are currently about 40 vaccines in various stages of pre-clinical and clinical 
development, as seen in Figure 2 (PATH 2018). 
 
There are broadly two approaches for development of an RSV Vaccine – by vaccinating 
young children/infants, and by vaccinating mothers in late pregnancy. While active 
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immunisation of infants would be the ideal solution for RSV prevention (Neuzil 2016), 
obtaining a good antibody response in the first 6 months of life when infants are most at 
risk (Higgins et al. 2016) is less reliable (Simões et al. 2018).  As a result, most vaccines 
targeting the paediatric population have been studied in children over 6 months, with the 
most promising candidate thought to be a live-attenuated vaccine currently in Phase 1 
trials (Karron et al. 2015). 
 
A potential solution to provide protection in this age group is maternal immunisation to 
prevent infant disease, similar to pertussis and tetanus immunisation in pregnancy. This 
approach is the closest to being fully developed, with a recombinant RSV vaccine currently 
in Phase 3 trials that would be completed in 2020 (Clinicaltrials.gov 2017). This is a 
promising area of development over the next few years and it may well be that a combined 
approach could help to reduce the disease burden of RSV Bronchiolitis. 
 
Conclusions 
 
Bronchiolitis continues to be a major cause of morbidity and healthcare cost despite over 
60 years of research. There is still very little evidence for any therapeutic pharmacological 
treatment, and whilst vaccination may be a potential way to reduce the burden of the 
disease, there is still much work to be done in terms of vaccine development as well as 
developing a coherent and cost-effective vaccination strategy. 
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Figure 1 – Cost effective use of Palivizumab [Shaded Area] (adapted from PHE 2015) 
Note: Chronological Age is calculated at the start of the RSV Season 
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 Table 1. Indications for hospital admission (NICE 2015) 
-apnoea (observed or reported) 
-persistent oxygen saturation less than 92% 
-inadequate oral fluid intake (50-75% of usual volume) 
-signs of severe respiratory distress  
respiratory rate>70/min,  
nasal flaring,  
grunting,  
severe chest wall recessions) 
 
Table Click here to download Table Table 1.docx 
 Table 2. Key Recommendations for hospital management (NICE 2015) 
Do not routinely perform chest x-rays or blood gases 
Do not routinely prescribe bronchodilators, nebulised adrenaline, steroids, nebulised 
hypertonic saline, antibiotics, leukotriene receptor antagonists or ribavirin 
Do not routinely perform physiotherapy 
Give supplemental oxygen if saturations < 92% in air  
Give fluids by nasogastric or orogastric tube in children with bronchiolitis if they cannot 
take in enough fluid by mouth 
Perform upper airway suctioning in babies with apnoea 
Provide written information for parents 
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 Table 3. Impending respiratory failure (NICE 2015) 
If any signs of exhaustion are present: 
listlessness 
decreased respiratory effort 
recurrent apnoea 
failure to maintain adequate oxygen saturation despite oxygen supplementation 
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